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1. Introduction
Human history has been closely linked to some animal species, and very specifically to dog.
This close relationship has endured, therefore the dog is considered the domestic specie closest
to man, because for today plays socially important roles as a member of many families and /
or as executor of activities that helps or facilitates human life. However, this closeness to man
has promoted, either by love or not, that care provided to dogs is increasing, and therefore on
the increase in life expectancy of these animals [1].
However, just as in humans, increased life expectancy of dogs, is often associated with
behavioral disturbances and cognitive deficits related with clinical signs of disorientation, loss
of social interaction, sleep disturbances, decreased general activity and progressive loss of
acquired memories [2-3]. Initially, these behavioral changes have been assumed by some
veterinarians, as evidence of senility [4]. It was recently proposed the term "Cognitive
Dysfunction Syndrome of Geriatric Dogs" (CDS), to describe the cognitive deficits observed
in some geriatric dogs [2,3,5,6], which seems being closely related with Alzheimer's disease
(AD), therefore, it is likely that CDS can be known as Dog's Alzheimer's disease [7,8,9,10]
Cognition refers to mental processes such as perception, consciousness, learning, memory and
making decisions, it allows obtaining information from the environment in order to interact
normally with environment [11, 12, 13, 14]. Nevertheless, cognition alterations could be
considered by some owners, as "normal" signs of aging, so these symptoms are always not
informed to veterinarian. Other common modifications are inability to recognize the family
members and to perform easy tasks such as eating and exercise, sleep-wake cycle changes are
common too [15]. These behavioral modifications can cause limitation of social interaction of
dogs; consequently can lead to rejection of certain owners to take care of these patients, so
increasing the risk of some pets to be sacrificed.
© 2013 Sanabria et al.; licensee InTech. This is an open access article distributed under the terms of the
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To date it has been identified several similarities between CDS and AD, therefore it has been
suggested that studies of geriatric canines that suffering CDS, could be a useful tool for
recognizing clinicopathological aspects yet not clarified of AD, and thereby possibly give more
effective management to disease [17-18]. However, despite the many similarities, there are also
some important differences, such as the involvement factors that predispose to humans, but
not dogs to diseases like EA. These factors including, gender [19] and background family [20].
Despite the large contribution that means owning a dog as the experimental model, which
develops a disease with many similarities to that seen in humans [17], shall be taken into
account that the results obtained from the use of this model is not always reflect a completely
accurate information. Therefore, there are several voices that suggest that the results obtained
in animals cannot always be extrapolated to humans because the techniques used to assess
cognitive functions differ in their ability to describe functions such as perception, discrimina‐
tion, storage and retrieval of cognitive flexibility [10]. However, after considering the possible
similarities and differences in EA and SDC, this chapter is to describe in detail the clinical and
patho-physiological characteristic of this canine dementia syndrome, likewise presents
diagnostic and therapeutic tools that seek to stop the progression clinical signs of the disease,
as well as discuss their clinic-pathologic similarities with the EA, and finally, discuss the facts
that today are considered to CDS as a valid experimental model for human neurodegenerative
diseases.
2. Clinical features
The behavioral abnormalities in geriatric dogs, are sometimes considered as traits of aging
process, however, it is important to differentiate between those behavioral alterations that are
related to serious damage of cognitive processes and slight decrease in psychomotor activity
or "normal aging" [2,13,15,16]. The intensity which behavioral changes affect each animal, are
characteristic of each patient and it is possible to identify a big variety of cognitive impairment,
for example, some dogs are unable to distinguish to family's members, whereas others dogs,
with lesser cognitive deficits, are able to remember instructions learned during training [17].
It is probably that altered urination habits, but not defecation habits, are the most frequent
signs observed by owners in pets that suffering CSD [17], nevertheless, polyuria can occur
without renal system diseases or without secondary environmental changes that prevent
access to appropriate area of evacuation.
Other common signs reported are episodes of confusion and disorientation [18], in which pet
gets lost in house or garden, going to wrong door or wrong side of the door. Clinical signs
include reduced interaction with owners, slowness to obey orders, alterations in the sleep-
wake cycle, excessive vocalization, exercise intolerance, difficulty climbing stairs, increased
irritability and new fears or phobias. [17,18].
Besides in wide variety of behavioral alterations reported, some authors have suggested to use
rating scales for diagnosing CDS in dogs, as proposed by Landsberg [3]. Landsberg's method
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sorts clinical signs in following topics: 1. Spatial disorientation and / or confusion, 2. Impaired
learning abilities and memory (loss of home grooming habits, incompetence to obey certain
orders or previously learned tasks), 3.Decreased activity or repetitive activities, 4.Alteration
and reduction of social interactions, 5.Decreased perception and / or responsiveness, 6.In‐
creased anxiety or restlessness, 7.Alteration of appetite associated with confusional states that
could prevent to find their food, 8.Alteration of day-night cycles (sleep-wake) [19, 20].
3. Prevalence
The life expectancy of humans and dogs has increased steadily over the past decades, due to
improved medical and health conditions available [21]. However, this increase in life expect‐
ancy has increased the prevalence of certain diseases related to aging, such as AD and CDS.
Therefore, after considering reports that suggest world presence of 52 million dogs around 7
years old [22], and taking into account that dogs over 7 years old could be considerate in
geriatric condition, it is possible to suppose that these both conditions could generate a big
population with great risk to suffer CDS [20. 23]. Some regional studies, have designed and
implemented various observational questionnaires, for the geriatric canine pet owners, that
try to identify behavioral changes in their pets and achieving determine CDS prevalence in
animals evaluated. Recently, an Italian study that included 124 geriatric dogs, revealed
prevalence about 50% of CDS, 75 dogs older than 7 years showed signs consistent with CDS
[13]. Similarly, another study [1] conducted with 180 dogs between 11 and 16 years old,
reported that 28% of dogs between 11 and 12 years showed some degree of cognitive impair‐
ment, while those individuals between 15 and 16 years had a probability close to 68% to
develop CDS, these data suggests a close relationship between the aging process and likelihood
of developing SDC.
However, although researches mentioned above are obviously important, it is worth noting
that their impact is restricted to local areas where researches were develop and, therefore, data
on the global prevalence of CDS have not yet been achieved, in part, due to tendency of pet
owners to not report to veterinarian the possible behavioral changes in geriatric pets [13],
which probably has limited accurate data to estimate the prevalence of CDS to worldwide.
4. Patho-physiological basis of CDS
To date have been identified several pathophysiological changes that matching for diseases
such as AD and CDS. Neurodegeneration defines pathological  neural death observed in
several neurodegenerative diseases such as CDS, which is characterized morphologically
by a decrease in the number of cholinergic neurons in hippocampus and cerebral cortex
(areas  especially  related  with  changes  in  behavior  and  cognitive  memory)  [3.24].  Al‐
though the causes of neuronal death is unknown, some authors have suggested to oxidative
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stress and accumulation of beta-amilode peptide (βA) as possible causal factors of clinical
signs observed in CDS [2].
βA peptide, which plays an important role in pathophysiology of canine dementia [2,8,25-26]
and AD [2], generates its neurotoxic effects by intra-neuronal accumulation [6], hence, it
induces degeneration of cholinergic neurons and it seems that quantity of accumulated βA is
associated with severity of clinical signs [1,10, 23,25,27, 28]. Reactive oxygen species (ROS),
which are recognized as inductors of oxidative stress, has been involved in presentation of
CDS and other demential syndromes as AD. Oxidative stress induces its deleterious effects on
neuronal cells and their effects are similar in dogs and older adults [2]. Mitochondria is the
first organelle involved in production of ROS due to its aerobic metabolism [29], nevertheless,
other sources could be also considerating as metabolic sources of ROS generation, such as
peroxisomes and release of oxidants by neutrophils. Similarly, exogenous influence such as
ionizing radiation, pollution and carcinogens, can contribute to production of free radicals in
mammalian systems [30].
According to some authors, oxidative damage is a key mechanism for development of diseases
associated with age that cause cognitive dysfunction [31]. Brain is highly predisposing to suffer
lesions induced by oxidative stress because it is common accumulation of oxidants substances
and because it is probably that protective mechanisms, such as superoxide dismutase and
vitamin E, can be less efficient to prevent alterations induced by oxidative stress [32], and thus
FR could potentially damage neuronal function causing cell death [2]. Neuronal death leads
to uncontrolled release of excitatory neurotransmitters such as acetylcholine, involved in
practically all cognitive functions especially in the memory, dopamine, which is associated
with control of movement (motor); norepinephrine, associated with wakefulness, attention
and serotonin, which is related to mood and sleep control [23,24,33,34]. In this sense, it is
possible suggest that neurochemical changes which occurring in brain of aged patients, are
the responsible of severity and clinical manifestation in patients with CDS.
5. Pathological lesions
Many morphological features which occur in brains of old dogs are similar to those observed
in the brains of aged humans [34]. These changes, which are related to age, include cortical
atrophy and increased ventricular spaces, morphological changes in meninges and choroid
plexus, changes in cerebral and meningeal vasculature; it is also evident degraded protein
accumulation and DNA damage [43 - 44.16]. Other lesions in dogs include inflammation of
meninges, gliosis, amyloid deposits, degeneration of myelin in white matter and accumulation
of oxidative stress products which have a close relationship with apoptotic processes. Apop‐
totic cell death has been described in brains from AD patients and in geriatric dogs affected
with CDS. Neuronal death by apoptosis processes is related to amyloid accumulation, and
according to various authors, may be the main responsible factor for age-related dementia [1].
These morphological changes are related to the characteristic signs of dementia in dogs [2,37,
41,42,45], therefore these has received much attention from researchers who have considered
dog as a model for studying human neurodegenerative diseases [29].
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In contrast,  brains of  patients  with AD show neurofibrillary plaques and intra-neuronal
formation  of  tau  protein  products.  Tau  protein  normally  is  a  essential  constituent  of
cytoskeleton in neurons [46], however, in people with AD, protein is hyper-phosphorylat‐
ed,  then  it  starts  a  process  which  induces  formation  of  paired  helical  filaments  which
saturate  the  cytoplasm  and  induce  destruction  of  microtubules  and  neurodegeneracion
[47-49].  Neurofibrillary  plaques  are  rare  in  other  species  and  their  presence  is  a  major
difference  between CDS and AD,  especially  because  dogs  not  develop these  structures,
because  tau's  protein  sequence  is  different  in  dogs  and  human  beings,  it  could  affect
formation of neurofibrillary plaques. However, recent studies suggest presence of imma‐
ture nascent plaques in brains of aged dogs [2,5].
6. Pathological lesions
Many morphological features which occur in brains of old dogs are similar to those observed
in the brains of aged humans [25]. These changes, which are related to age, include cortical
atrophy and increased ventricular spaces, morphological changes in meninges and choroid
plexus, changes in cerebral and meningeal vasculature, it is also evident degraded protein
accumulation and DNA damage [35, 36, 37]. Other lesions in dogs include inflammation of
meninges, gliosis, amyloid deposits, degeneration of myelin in white matter and accumulation
of oxidative stress products which have a close relationship with apoptotic processes. Apop‐
totic cell death has been described in brains from AD patients and in geriatric dogs affected
with CDS. Neuronal death by apoptosis processes is related to amyloid accumulation, and
according to various authors, may be the main responsible factor for age-related dementia [38].
These morphological changes are related to the characteristic signs of dementia in dogs
[10,39,40,41,42], therefore these has received much attention from researchers who have
considered dog as a model for studying human neurodegenerative diseases [2].
In  contrast,  brains  of  patients  with  AD show neurofibrillary  plaques  and intraneuronal
formation  of  tau  protein  products.  Tau  protein  normally  is  a  essential  constituent  of
cytoskeleton in neurons [43], however, in people with AD, protein is hyperphosphorylat‐
ed,  then  it  starts  a  process  which  induces  formation  of  paired  helical  filaments  which
saturate the cytoplasm and induce destruction of microtubules and neurdegeneracion [44,
45]. Neurofibrillary plaques are rare in other species and their presence is a major differ‐
ence  between  CDS  and  AD,  especially  because  dogs  not  develop  these  structures,  be‐
cause tau's protein sequence is different in dogs and human beings, it could affect formation
of neurofibrillary plaques. However, recent studies suggest presence of immature nascent
plaques in brains of aged dogs [10, 23].
Neurochemical  changes  such  as  low  levels  of  dopamine,  norepinephrine,  serotonin,
acetylcholine,  choline  acetyl-transferase  and  decreased  number  of  D2  receptors,  are
characteristics  that  are  commonly  observed  in  CDS  and  AD  [34].  However,  there  are
disease-specific  changes as  decrease of  muscarinic  receptor  number [46]  and increase of
activity  of  enzyme  acetylcholinesterase,  which  are  factors  present  only  in  AD  [47].  In
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contrast,  in  affected  dogs  have  been  detected  increased  MAO  activity  and  increased
sensitivity to glutamate neurotransmitter, which is capable of initiating processes neurotox‐
icity [23]. However, the most consistent alteration in brains of dogs and humans with AD
is  βA peptide accumulation in hippocampus and frontal  cortex (areas  especially  related
cognitive behavioral changes) [10, 48]. In neuron, βA is initially concentrated in microdo‐
mains of plasma membrane in neurons of the prefrontal cortex and subsequently affects
other brain regions such as the parietal and entorhinal cortices [49].
7. Diagnosis
Veterinarians commonly faced with behavioral disturbances in older dogs, however, although
it is true that CDS may be the main responsible for these changes, it is also true that behavioral
disturbances could be induced by other multifactorial causes [6,10,28]. Therefore, considering
the variety and inspecificity of clinical signs associated with CDS, it is important to use clinical
history for obtain patient-specific data, which ensures that owners had provided a complete
list of all medical and behavioral signs observed in their pets. This information could provide
a solid support in finding potential medical problems that may be responsible for the devel‐
opment or exacerbation of clinical signs [3], furthermore this information along with clinical
and neurological examination, which can be developed using assessment tests cognitive, may
let to veterinarian obtain an early diagnosis [23].
However, we must emphasize difficulty for obtaining accurate information, because in many
cases information obtained from pet owners could be little objective, possibly leading to false
diagnosis. Thus, shortage of reliable diagnostic tests to ensure presence or absence of disease,
gives to early identification of clinical signs a crucial role in establishment of effective treat‐
ment, capable of improvement the quality of life of affected patients. In this sense, and
according to some authors, the most effective way to detect the condition is through the
routinely establishment of behavioral questionnaires in geriatric dogs [2.10]. These question‐
naires that ask to owners about your pet's behavior, which have been obtained from various
researches [15.35], pretend classifying the behavior of affected patients. Within these cognitive
evaluation questionnaires, neuropsychological tests are looking classify systematic cognitive
impairment through methods such as modified apparatus of Wisconsin General Test (Uni‐
versity of Toronto), in which the dogs are rewarded for each correct answer they obtain.
Overall, in this test the dogs have access to a removable tray containing three food wells built
in, which can be covered to test visual learning and memory [50, 51].
These neurophysiological tests allow assessment objective and quantitative of deficits in
learning and memory, without relying on questionnaires applied to owners. These evaluation
tests look for three specific objectives: 1. Identification of non-subjective cognitive changes that
are characteristic of aging in dogs, 2. Characterization of the neurobiological basis of decline
in cognitive abilities due to aging, and 3. Preparation of potential interventions in order to
eliminate or minimize the adverse effects on quality of life [2, 50, 51].
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Although learning and memory are quite susceptible to decline with aging, it is necessary
evaluating too the spatial memory (the ability to remember the location of food, for example)
and the object recognition memory (the ability to recall objects seen with 10-120 seconds ahead)
[10], because it is well accepted that these both two memory types are affected in neurodege‐
nerative processes, therefore several studies have developed scales that evaluate the spatial
memory and the recognition abilities for indirect evaluation of dementia in dogs [52]. For
example, it has been proposed a dementia evaluation index that discriminates between normal,
pre-dementia and dementia states [17]. ARCAD scale (assessing cognitive and affective
disorders associated with age), where dog's behavior is assessed indirectly through a ques‐
tionnaire applied to owner, in order to assess the deficit by a scale evaluation of 1 to 5 [53].
Although various tests have shown be able to diagnose the cognitive dysfunction syndrome,
we must consider that the results obtained with each test, can vary according to the test, it is
possible that cognitive skills, may have a different meaning on the outcome of the test [11.13].
Moreover, besides the possibility to compare results obtained in each test, it is necessary to
correlate the results of behavior modifications in dogs examined with paraclinical test results,
such as electroencephalography. This relationship could establish whether the test results are
able to correlate disturbances in learning, memory and cognitive with disorders of brain
circuits that are involved in CDS. It is possible that paraclinical tests can predict dysfunctional
brain diseases in dogs?
Finally, it is worth mentioning that several cognitive domains that are affected during the CDS
(language, memory, visuospatial skills) and observation of a sign, is not sufficient for begin‐
ning a treatment. However, the onset of cognitive impairment in some specific domain could
be related into a worsening of other existing signs, therefore it is important following up clinical
evaluations routinely [10].
In conclusion, to determine if a dog shows signs of cognitive dysfunction, the veterinarian
must rely on information provided by the owner in the medical record, however, the design
and implementation of a questionnaire, and possibly paraclinical tests, are necessary to
detected signs of CDS during the early stages of development, especially if it comes from
animals that have previously had a high level of training [3].
8. Therapeutic alternatives for the treatment of CDS
Currently there are several therapeutic strategies that have been developed along different
studies in geriatric dogs affected by CDS.
9. Behavioral type therapy
One consequence of age-associated diseases in dogs is loss of memories acquired during
professional or home training, therefore dog may lose its ability to perform simple tasks or to
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answer previously learned commands. Faced with this kind of behavioral changes, which may
be observed in patients with CDS, the establishment of behavioral therapy, in the early stages
of the disease, has been suggested as appropriate, when it is accompanied with additional
therapeutic tools like drug treatment. Re-training dogs with cognitive dysfunction requires
patience and it is necessary to use simple commands with a clear reward and it is important
that re-training begins as soon as possible to prevent the development of unwanted behaviors
in the dog [2.6].
10. Pharmacological treatment alternatives
Drug therapy is aimed, on the one hand, restoring neurotransmitter concentrations and, on
other hand, preventing too rapid advancement of neurodegenerative process [54, 55]. Most
treatments used for people affected with AD, have not yet been tested in dogs, nevertheless it
is necessary perform clinical studies which be able to clarify which treatments work and which
do not. However, there are some options available as selegiline, this was the first therapeutic
agent approved by the FDA in 1998 for use in dogs [5.56], this is a selective irreversible inhibitor
of the enzyme monoamine oxidase B (MAO B) which increases the concentration of dopamine
in brain and it seems to prevent oxidative stress, therefore it could decrease neuronal death.
The therapeutical efficacy of selegiline has been shown by studies that verify a decrease in the
progression of degenerative changes in AD patients and a significant improvement in dogs
with CDS [1]. Therefore, regulating the concentration of neurotransmitters has been consid‐
ered the main therapeutic alternative for treatment of CDS in dogs, nevertheless, it is possible
that new studies could verify a major efficiency of other drugs, for example drugs with
anticholinenterase activity or NMDA blockers drugs, which have been effective for treatment
of AD, could be could be effective for dogs.
11. Nutritional therapies
After recognizing the role of ROS (reactive oxygen species) in neurodegenerative diseases,
some researchers have recommended reduce the amount of free radicals formed from
exogenous influences or include in habitual diet nutritional supplements capable to scavenge
ROS, nowadays it is well accepted which these supplements can maximize the benefits of
psychopharmacological therapy, improving quality of life promoting positive changes in
behavior of canines that suffering CDS [5, 57].
Within the beneficial effects attributed to the antioxidant products, could be considered
potentiating of mitochondrial function during aging, which resulting in decreased production
of ROS [2-3,8,58]. As a result of these effects, some authors have suggested that dogs suffering
CDS, and have received a supplement of antioxidants in diet, show an improvement in
cognitive ability [59]. Besides, a variety of studies have shown that intake of fruits and
vegetables may decrease the risk of cognitive declines associated with age in rodents, dogs,
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and even humans, attributing this property to its antioxidant and anti-inflammatory capabil‐
ities [3,5,58].
There are several compounds which have been described their antioxidant activity, among
them we can mention the vitamins E and C, beta-carotene, selenium, L-carnitine and alpha
lipoic acid, all them have shown to improve mitochondrial function and likely by some
neuroprotective effect it is explains the improvement of memory. Similarly, some authors
suggest that GingkoBiloba, besides possessing antioxidant effect, has a variety of properties
such as anti-inflammatory, cerebral vasodilator, mitochondrial function enhancer and MAO
enzyme inhibitor [3,13,60], therefore, it has been suggested that GingkoBiloba could reduce
the severity of clinical symptoms observed in patients with CSD. Additionally, natural
compounds of animal origin, such as propolis, which our research group studies its neuro‐
protective properties, currently are valued for their antioxidant and neuroprotective qualities
[61], however, there are still no studies describing the positive effects of this compound on
CDS.
Other group of compounds with ROS activity is composed of certain molecules classified as
mitochondrial cofactors (acidolipoico, L-carnitine) which can potentiate the function of
mitochondria, resulting in a lower production of ROS during aerobic respiration. Nutritional
supplementation with these mitochondrial cofactors induces their cell acumulation where they
restore mitochondrial efficiency and reduces oxidative damage to RNA [62]. It has also been
suggested the use of mitochondrial cofactors along with antioxidants, in order to cause an
improvement in learning processes and memory, through a synergistic action [19].
It is probably the best evidence of positive effect of dietary supplementation on cognitive
impairment in dogs, was found after applying neuropsychological tests for a period exceeding
two years. The study aimed to supplement diet of dogs with mitochondrial cofactors and
antioxidants of broad spectrum to enhance antioxidant defenses and reduce ROS accumula‐
tion. Results indicated that these products slowed the age associated cognitive decline [3].
However, to develop a diet supplemented with antioxidants, it should be noted that the
selection of components, the ranges of dosage and route of administration, vary considerably
between species. Also, some antioxidants are absorbed more quickly than others, species-
specific factors, metabolic differences due to inherent bioavailability: thus, different species
may benefit from different types of antioxidants, but not all species may benefit from the same
antioxidants [2].
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